|1.||Bassett, D: 1 article (04/2015)|
|2.||Hagelstrom, R T: 1 article (04/2015)|
|3.||Shea, T C: 1 article (04/2015)|
|4.||McDonagh, K T: 1 article (04/2015)|
|5.||Tibes, R: 1 article (04/2015)|
|6.||Frazer, N: 1 article (04/2015)|
|7.||Garcia, R: 1 article (04/2015)|
|8.||Schroeder, K: 1 article (04/2015)|
|9.||Von Hoff, D: 1 article (04/2015)|
|10.||Beaudry, C: 1 article (04/2015)|
11/15/2013 - "The semi-synthetic lignan terameprocol inhibits the transcription of several inflammatory and oncogenic genes and has been evaluated for its anti-cancer properties. "
08/15/2009 - "The analogs were evaluated for cytotoxicity in four cancer cell lines and compared to NDGA and tetra-O-methyl-NDGA (M4N) (1a). "
03/01/2008 - "In a phase I clinical trial in patients (25 evaluable) with solid tumors administered intravenous terameprocol, 8 patients exhibited stable disease and 17 had progressive disease; the drug was generally well tolerated. "
03/01/2008 - "Terameprocol, a novel, semisynthetic derivative of a naturally occurring plant lignan, is under development by Erimos Pharmaceuticals LLC for the potential treatment of cancer. "
09/01/2007 - "The terameprocol CPE formulation showed no overt toxicities in tumor-bearing mice. "
04/01/2012 - "Phase I study of terameprocol in patients with recurrent high-grade glioma."
03/01/2008 - "At the time of publication, terameprocol was in phase I or I/II clinical development for the treatment of glioma, treatment-refractory solid tumors and cervical dysplasia; a phase I clinical trial was also planned in patients with hematological cancers. "
04/01/2012 - "The long-term stability noted in some patients and the lack of associated myelosuppression suggest that terameprocol could be safely combined with radiation and temozolomide in newly diagnosed high-grade gliomas."
|3.||Cervical Intraepithelial Neoplasia
|4.||Lung Neoplasms (Lung Cancer)
01/01/2011 - "This study examined the effects of terameprocol administration on survivin transcription and expression in HCC2429 and H460 lung cancer cells. "
01/01/2011 - "Further study is warranted to assess the potential of terameprocol as an agent that may enhance the therapeutic ratio of radiotherapy in lung cancer."
04/01/2015 - "Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias."
04/01/2015 - "Terameprocol can be safely administered to advanced leukemia patients, sufficient drug exposure was obtained and clinical activity and biomarker modulation were observed."
|2.||Thymidine Monophosphate (TMP)
|3.||Polyethylene Glycols (Polyethylene Glycol)
|4.||Dimethyl Sulfoxide (DMSO)
|6.||Nordihydroguaiaretic Acid (Masoprocol)
|7.||Succinic Acid (Succinate)
|10.||Mesna (Coenzyme M)
|1.||Heterologous Transplantation (Xenotransplantation)